Switch to Myfortic® — Go Beyond Graft Protection with Better GI Tolerability and Quality of Life

Switch to Myfortic^® — Go Beyond Graft Protection with Better GI Tolerability and Quality of Life

Conversion to Myfortic^® significantly reduced GI complications, with lower Gastrointestinal Symptom Rating Scale (GSRS) scores, which may support better drug adherence¹

^aP<0.0001 for all subscales vs baseline (MMF)
^bA difference ranging from 0.2 to 0.5 is indicative of clinical relevance, as defined by minimal important difference Adapted from Chan L, et al. Transplantation. 2006¹

Patients on Myfortic^® reported better scores across all Gastrointestinal Quality of Life Index (GIQLI) dimensions¹

Switching to Myfortic^® did not compromise graft protection efficacy, could even lead to lower incidences of acute kidney rejection and BPAR in renal transplant patients^2,3

Abbreviations:
BPAR, Biopsy-proven acute rejection; EC MPS, enteric-coated mycophenolate sodium; GI, gastrointestinal; GIQLI, Gastrointestinal Quality of Life Index; GSRS, Gastrointestinal Symptom Rating Scale; MMF, mycophenolate mofetil

References:
1. Chan L, et al. Transplantation. 2006;81(9):1290-1297; 2. Sollinger, HW, et al. Transplantation. 2010;89(4):446-451; 3. Myfortic PI, Singapore 2021; 4. Nashan B, et al. Transplant Proc. 2006;38:2856–2859; 5. Cooper M, et al. Transplant Rev (Orlando). 2012;26(4):233–240.

20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439

Phone: +65 6722 6010

This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.

FOR HEALTHCARE PROFESSIONALS ONLY

Please visit https://www.novartis.com/sg-en/product-list/myfortic to access or download the Package Insert.
Alternatively, please scan this code for more Information about this medicine.

FA-11476020, 2027Aug01

×

Medical Information Request

Ask Speakers